Dr. Chun Cao – Network Science
Academician/Research Scholar
Congratulations,Dr. Chun Cao – Network Science , on winning the esteemed Best Researcher Award from Sfconference! Your dedication, innovative research, and scholarly contributions have truly made a significant impact in your field. Your commitment to advancing knowledge and pushing the boundaries of research is commendable. Here’s to your continued success in shaping the future of academia and making invaluable contributions to your field. Well done!
Wishing you continued success and many more milestones in your illustrious research journey. Your impact on the field is truly commendable and serves as a beacon of inspiration for aspiring researchers.
Warmest congratulations once again on this well-deserved recognition!
Professional Profiles:
Education:
-
- Doctor degree of medicine in West China Clinical Medical School of Sichuan univeresity.
- Major; Hematology (Stem cell transplantation)
- Bechelor and Master degree of Medicine in West china Clinical Medical School of sichuan University.
Awards:
1.The second prize for Medical bilingual lecture contest in the second affiliated Hospital of chongqing Medical university.
2.The best teaching plan award for Medical bilingual lecture contest in the second affiliated Hospital of chongqing Medical university.
publication;
1. Cao C, Wang T, Luo Y, Zhang Y, Dai YY, Shen Y. Comprehensive analysis of cuproptosis-associated LncRNAs predictive value and related CeRNA network in acute myeloid leukemia. Heliyon. 2023;9(12):e22532. Published 2023 Nov 25. doi:10.1016/j.heliyon.2023.e22532
2. Cao C, Zhang L, Sorensen MD, et al. D-2-hydroxyglutarate regulates human brain vascular endothelial cell proliferation and barrier function [published correction appears in J Neuropathol Exp Neurol. 2023 Nov 07;:]. J Neuropathol Exp Neurol.
2023;82(11):921-933. doi:10.1093/jnen/nlad0723. Cao C, Li X, Liu T, Zhang L, Shen K, Zhu H. Human organic cation transporter 1 protein levels of granulocytes can optimize imatinib therapy in patients with chronic myeloid leukemia. Acta Haematol. 2015;133(2):199-204. doi:10.1159/0003654374. Cao C, Liu T, Zhu H, Wang L, Kai S, Xiang B. Bortezomib-contained chemotherapy and thalidomide combined with CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) play promising roles in plasmablastic lymphoma: a case report and literature review. Clin Lymphoma Myeloma Leuk. 2014;14(5):e145-e150. doi:10.1016/j.clml.2014.03.002
5. Cao C, Liu S, Lou SF, Liu T. The +252A/G polymorphism in the Lymphotoxin-α gene and the risk of non-Hodgkin lymphoma: a meta-analysis. Eur Rev Med Pharmacol Sci. 2014;18(4):544-552.
6.Cao C, Liu T, Lou S, Liu W, Shen K, Xiang B. Unusual presentation of duodenal plasmablastic lymphoma in an immunocompetent patient: A case report and literature review. Oncol Lett. 2014;8(6):2539-2542. doi:10.3892/ol.2014.26047.Sun Y, Wei C, Cao C, et al. New Strategy of Acute Graft-vs-Host Disease: Investigation of a Reduced Dose of Antithymocyte Globulin in Haploidentical Hematopoietic Stem Cell Transplantation. Transplant Proc. 2019;51(3):890-895. doi:10.1016/
j.transproceed.2018.10.028